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Abstract
Following an application from H.J. Heinz Supply Chain Europe B.V., submitted for authorisation of a
health claim pursuant to Article 14 of Regulation (EC) No 1924/2006 via the Competent Authority of
the Netherlands, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to
deliver an opinion on the scientiﬁc substantiation of a health claim related to ‘Nutrimune®’ and
immune defence against pathogens in the gastrointestinal (GI) tract and upper respiratory tract (URT).
The food ‘Nutrimune®’ (a pasteurised cow’s skim milk fermented with Lactobacillus paracasei CBA L74)
which is the subject of the health claim is sufﬁciently characterised. The Panel considers that immune
defence against pathogens in GI tract and URT is a beneﬁcial physiological effect. One human
intervention study from which conclusions can be drawn showed an effect of ‘Nutrimune®’ on immune
defence against pathogens in the GI tract and the URT, and the results from one animal study could
support an effect of ‘Nutrimune®’ on defence against pathogens in the GI tract. However, there were
inconsistencies in the reporting of the process and criteria used for the diagnosis of URTI in the human
intervention study, the results of this study have not been replicated, and no evidence was provided
for a plausible mechanism by which ‘Nutrimune®’ could exert the claimed effect in vivo in humans. The
Panel concludes that the evidence provided is insufﬁcient to establish a cause and effect relationship
between the consumption of ‘Nutrimune®’ and immune defence against pathogens in the
gastrointestinal and upper respiratory tracts.
© 2017 European Food Safety Authority. EFSA Journal published by John Wiley and Sons Ltd on behalf
of European Food Safety Authority.
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Summary
Following an application from H.J. Heinz Supply Chain Europe B.V., submitted for authorisation of a
health claim pursuant to Article 14 of Regulation (EC) No 1924/2006 via the Competent Authority of
the Netherlands, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to
deliver an opinion on the scientiﬁc substantiation of a health claim related to ‘Nutrimune®’ and
immune defence against pathogens in the gastrointestinal and upper respiratory tracts.
The scope of the application was proposed to fall under a health claim referring to children’s
development and health. The application included a request for the protection of proprietary data.
The general approach of the NDA Panel for the evaluation of health claim applications is outlined in
the EFSA general guidance for stakeholders on health claims applications and the guidance on the
scientiﬁc requirements for health claims related to the immune system, the gastrointestinal tract and
defence against pathogenic microorganisms.
The food that is the subject of the health claim is ‘Nutrimune®’. The Panel considers that
‘Nutrimune®’ (a pasteurised cow’s skim milk fermented with Lactobacillus paracasei CBA L74) is
sufﬁciently characterised.
The claimed effect proposed by the applicant is ‘support of the immune defence in the
gastrointestinal and upper respiratory tract’. The target population proposed by the applicant is ‘young
children aged 12–48 months old’. The Panel considers that immune defence against pathogens in the
gastrointestinal and upper respiratory tracts is a beneﬁcial physiological effect.
The applicant identiﬁed two human intervention studies (one published and one unpublished) which
investigated the effects of ‘Nutrimune®’ on clinical outcomes related infectious diseases of the
gastrointestinal (GI) tract and/or upper respiratory tract (URT) in children as being pertinent to the
claim.
The Panel notes that one human intervention study from which conclusions could be drawn showed
an effect of ‘Nutrimune®’ on immune defence against pathogens in the GI tract and the URT. The
Panel also notes, however, inconsistencies in the reporting of the process and criteria used for the
diagnosis of upper respiratory tract infections (URTI), and that the results of the study have not been
replicated.
The applicant provided one animal study for the scientiﬁc substantiation of the claim. The
Panel considers that the results from this animal study may be in line with an effect of ‘Nutrimune®’ on
defence against pathogens in the GI tract, albeit the effects shown are small, and found in a model
that is very different from a normal infection in humans.
The applicant provided three in vitro studies in relation to the mechanism by which ‘Nutrimune®’
could exert the claimed effect. Based on the information provided, the Panel considers that the results
of these studies do not provide evidence for a plausible mechanism by which ‘Nutrimune®’ could exert
the claimed effect in vivo in humans.
In weighing the evidence, the Panel took into account that one human intervention study from
which conclusions could be drawn showed an effect of ‘Nutrimune®’ on immune defence against
pathogens in the GI tract and the URT, and that the results from one animal study could support an
effect of ‘Nutrimune®’ on defence against pathogens in the GI tract. The Panel also took into account
the inconsistencies in the reporting of the process and criteria used for the diagnosis of URTI in the
human intervention study, that the results of this study have not been replicated, and that no evidence
was provided for a plausible mechanism by which ‘Nutrimune®’ could exert the claimed effect in vivo
in humans.
On the basis of data presented, the Panel concludes that the evidence provided is insufﬁcient to
establish a cause and effect relationship between the consumption of ‘Nutrimune®’ and immune
defence against pathogens in the gastrointestinal and upper respiratory tracts.
‘Nutrimune®’ and immune defence against pathogens
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1. Introduction
1.1. Background and Terms of Reference as provided by the requestor
Regulation (EC) No 1924/20061 harmonises the provisions that relate to nutrition and health claims,
and establishes rules governing the Community authorisation of health claims made on foods. As a
rule, health claims are prohibited unless they comply with the general and speciﬁc requirements of this
Regulation, are authorised in accordance with this Regulation, and are included in the lists of
authorised claims provided for in Articles 13 and 14 thereof. In particular, Articles 14–17 of this
Regulation lay down provisions for the authorisation and subsequent inclusion of reduction in disease
risk claims and claims referring to children’s development and health in a Community list of permitted
claims.
According to Article 15 of this Regulation, an application for authorisation shall be submitted by the
applicant to the national competent authority of a Member State, which will make the application and
any supplementary information supplied by the applicant available to the European Food Safety
Authority (EFSA).
1.2. Interpretation of the Terms of Reference
EFSA is requested to evaluate the scientiﬁc data submitted by the applicant in accordance with
Article 16(3) of Regulation (EC) No 1924/2006. On the basis of that evaluation, EFSA will issue an
opinion on the scientiﬁc substantiation of a health claim related to: ‘Nutrimune®’ and immune defence
against pathogens.
The present opinion does not constitute, and cannot be construed as, an authorisation for the
marketing of ‘Nutrimune®’, a positive assessment of its safety, nor a decision on whether ‘Nutrimune®’
is, or is not, classiﬁed as a foodstuff. It should be noted that such an assessment is not foreseen in the
framework of Regulation (EC) No 1924/2006.
It should also be highlighted that the scope, the proposed wording of the claim, and the conditions
of use as proposed by the applicant may be subject to changes, pending the outcome of the
authorisation procedure foreseen in Article 18(4) of Regulation (EC) No 1924/2006.
2. Data and methodologies
2.1. Data
2.1.1. Information provided by the applicant
2.1.1.1. Food/constituent as stated by the applicant
According to the applicant, the food for which a health claim is made is ‘Nutrimune®’, which is a
heat-treated fermented milk, fermented with Lactobacillus paracasei CBA L74.
2.1.1.2. Health relationship as claimed by the applicant
According to the applicant, consumption of ‘Nutrimune®’ supports the immune defence, thus
maintaining immune defence in the gastrointestinal (GI) and upper respiratory tracts, as demonstrated
by subsequent reduced occurrence, of both GI and upper respiratory tract infections in combination
with a corresponding change in positive stimulation of elements of innate and acquired immunity.
2.1.1.3. Mechanism(s) by which the food exerts the claimed effect as proposed by the
applicant
According to the applicant, the mechanism involved in the maintenance of immune defence of the
GI and upper respiratory tracts by ‘Nutrimune®’, may be at least in part related to a positive
stimulation of innate and acquired immunity. A negative correlation between faecal concentrations of
a- and b-defensins, cathelicidin (LL-37) and secretory immunoglobulin A (sIgA) and the number of
infectious episodes has been demonstrated. In a non-human model, a signiﬁcant positive modulation
of non-immune defence mechanisms has been also demonstrated consisting of stimulation of epithelial
cells growth, differentiation, permeability and mucus production.
1 Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and health
claims made on foods. OJ L 404, 30.12.2006, p. 9–25.
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2.1.1.4. Wording of the health claim as proposed by the applicant
The applicant has proposed the following wording for the health claim: ‘Nutrimune®’ supports the
immune defence in the gastrointestinal and upper respiratory tract of young children.
2.1.1.5. Speciﬁc conditions of use as proposed by the applicant
According to the applicant, doses of 7 g of ‘Nutrimune®’, in spray-dried form, should have been
consumed daily for a period of 3 months to obtain the claimed effect. The given amount of
‘Nutrimune®’ can be obtained through consumption of a range of products to which ‘Nutrimune®’ can
be added. It is anticipated that ‘Nutrimune®’ will be applied as an ingredient in liquid, semiliquid and
dry forms to a variety of products.
The target population proposed by the applicant are young children aged 12–48 months old.
2.1.2. Data provided by the applicant
Health claim application on ‘Nutrimune®’ and immune defence against pathogens pursuant to
Article 14 of Regulation 1924/2006, presented in a common and structured format as outlined in the
Scientiﬁc and technical guidance for the preparation and presentation of applications for authorisation
of health claims.2
As outlined in the General guidance for stakeholders on health claim applications (EFSA NDA Panel,
2016a), it is the responsibility of the applicant to provide the totality of the available evidence.
This health claim application includes a request for the protection of proprietary data in accordance
with Article 21 of Regulation (EC) No 1924/2006. Data claimed to be proprietary and conﬁdential by
the applicant include:
• Data related to the unpublished human study (Corsello et al., 2015) are proprietary to H.J.
Heinz Supply Chain Europe B.V.;
• Data related to the primers sequence presented in the application are conﬁdential to H.J. Heinz
Supply Chain Europe B.V.
2.2. Methodologies
The general approach of the NDA Panel for the evaluation of health claims applications is outlined
in the EFSA general guidance for stakeholders on health claim applications (EFSA NDA Panel, 2016a).
The scientiﬁc requirements for health claims related to the immune system, the gastrointestinal
tract and defence against pathogenic microorganisms are outlined in a speciﬁc EFSA guidance (EFSA
NDA Panel, 2016b).
3. Assessment
3.1. Characterisation of the food/constituent
The food that is the subject of the health claim is ‘Nutrimune®’.
‘Nutrimune®’ is cow’s skim milk fermented with Lactobacillus paracasei CBA L74. Fermentation is
followed by pasteurisation to kill viable bacteria. The ﬁnal product is available as a spray-dried milk
powder containing at least 7 x 1010 colony-forming units (cfu) of non-viable L. paracasei CBA L74. It is
anticipated that ‘Nutrimune®’ will be used as an ingredient in liquid, semiliquid and dry forms in a
variety of food products.
Lactobacillus paracasei CBA L74 has been deposited in the internationally recognised Belgian
collection BCCM/LMG with the International Depository Access Number LMG P-24778.
The species was identiﬁed using repetitive extragenic palindromic PCR (rep–PCR) and a speciﬁc
PCR. A single primer ﬁngerprinting technique was used to identify the strain. Upon a request for
clariﬁcation from EFSA, the applicant provided results of the 16S rRNA and 23S rRNA gene sequence
analysis, conﬁrming the identiﬁcation of the bacterial strain.
Detailed speciﬁcations of the manufacturing process, nutritional composition of the ﬁnal product,
and information on stability, were provided by the applicant.
2 EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientiﬁc and technical guidance for the preparation and
presentation of an application for authorisation of a health claim (revision 1). EFSA Journal 2011;9(5):2170, 36 pp.
doi:10.2903/j.efsa.2011.2170
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The Panel considers that the food ‘Nutrimune®’ (a pasteurised cow’s skim milk fermented with
Lactobacillus paracasei CBA L74), which is the subject of the health claim, is sufﬁciently characterised.
3.2. Relevance of the claimed effect to human health
The claimed effect proposed by the applicant is ‘support of the immune defence in the
gastrointestinal and upper respiratory tract’. The target population proposed by the applicant is ‘young
children aged 12–48 months old’.
In response to a request for clariﬁcation from EFSA, the applicant indicated that the claimed
effect relates to ‘immune defence against pathogens in the gastrointestinal and upper respiratory
tracts’.
As explained in the Guidance on the scientiﬁc requirements for health claims related to the immune
system, the GI tract and defence against pathogenic microorganisms (EFSA NDA Panel, 2016b), the
scientiﬁc evidence for the substantiation of health claims related to defence against pathogens in the
upper respiratory tract (URT) can be obtained from human intervention studies showing an effect on
clinical outcomes related to infections (e.g. incidence, severity and/or duration of symptoms) of the
URT (e.g. rhinitis, pharyngitis, sinusitis, otitis media, common cold). Upper respiratory tract infections
(URTIs) clinically diagnosed by the primary care or hospital physician following well deﬁned criteria can
be used as an appropriate outcome variable for the scientiﬁc substantiation of the claim, provided that
adequate exclusion criteria for the most common non-infectious causes (e.g. allergic diseases) of the
signs and symptoms used for diagnosis of the upper respiratory infection have been applied (i.e.
differential diagnosis). Microbiological data could also be used to ascertain the infectious aetiology of
clinically diagnosed episodes.
For health claims related to defence against pathogens in the GI tract, clinical outcomes related to
GI infections, for example incidence, severity and/or duration of diarrhoeal episodes, could be used.
The infectious aetiology of diarrhoeal episodes, however, should be ascertained. In this context, GI
infection clinically diagnosed by the primary care or hospital physician following well deﬁned criteria
can be used as an appropriate outcome variable for the scientiﬁc substantiation of the claim, provided
that adequate exclusion criteria for the most common non-infectious causes of diarrhoea have been
applied. Microbiological data could also be used to ascertain the infectious aetiology of diarrhoeal
episodes.
Other outcome variables, such as changes in relevant immunological markers, may provide
supportive evidence on the mechanism (e.g. through the activation of the immune system) by which
the food/constituent could exert the claimed effect, but alone are not appropriate for the
substantiation of claims related to immune defence against pathogens.
The Panel considers that immune defence against pathogens in the GI and upper respiratory tracts
is a beneﬁcial physiological effect.
3.3. Scientiﬁc substantiation of the claimed effect
The applicant performed a literature search in the Cochrane library, PubMed and Clinical Trials
databases using the following key words: Lactobacillus paracasei and CBA L74, immune defence
against pathogens and/or clinical outcomes of infections, and human and/or in vivo data. No limits
were set. Additionally, hand searching was used to identify publications on Lactobacillus paracasei CBA
L74.
As a result, the applicant identiﬁed two human intervention studies (one published and one
unpublished) which investigated the effects of ‘Nutrimune®’ on clinical outcomes related infectious
diseases of the GI and/or respiratory tracts in children as being pertinent to the claim. The applicant
also provided one animal efﬁcacy study and three in vitro studies in relation to the mechanism by
which ‘Nutrimune®’ could exert the claimed effect.
3.3.1. Human intervention (efﬁcacy) studies
In a randomised, double-blind, one-centre (performed in paediatric centre in Naples), three-arm
parallel study, Nocerino et al. (2015) evaluated the effect of ‘Nutrimune®’ and of rice fermented with
Lactobacillus paracasei CBA L74 compared with placebo on the incidence of common infectious
diseases (CID) in healthy young children aged 12–48 months who attended day care or preschool at
least 5 days per week.
‘Nutrimune®’ and immune defence against pathogens
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The exclusion criteria were: concomitant chronic systemic diseases, congenital cardiac defects,
gastrointestinal or urinary or respiratory tract surgery, active tuberculosis, autoimmune diseases,
immunodeﬁciency, chronic inﬂammatory bowel diseases, cystic ﬁbrosis, metabolic diseases, history of
suspected or challenge-proved food allergy, lactose intolerance, malignancy, chronic pulmonary
diseases, malformations of gastrointestinal or urinary or respiratory tract, severe malnutrition, and use
of ‘pre/pro/synbiotics’, antibiotics or immune stimulating products in the 2 weeks before the enrolment.
A sample size of 118 children per group was calculated for a power of 0.92 and a = 0.05, assuming
the occurrence of at least one episode of infection in 80% of children in the placebo group and at
least one episode of infection in 60% of children in both intervention groups. Randomisation was
performed with a computer-generated randomisation sequence using blocks of 36 subjects per family
paediatrician. The investigators were blinded in relation to the allocation of the participants, the
intervention, laboratory analysis and statistical analysis.
A total of 432 children (51% male, mean age 32 months, n = 144 per group) were randomised to
receive daily either ‘Nutrimune®’, rice fermented with Lactobacillus paracasei CBA L74, or placebo
(maltodextrin) for 3 months (January–March 2012). All tested products were given as a powder
(7 g/day) to be diluted in a maximum of 150 mL of cow’s milk or water. Parents were instructed to
exclude ‘prebiotics, probiotics, synbiotics and immune stimulating products’ during the intervention
period. Compliance was deﬁned as the consumption of at least 80% of the assigned treatment during
the study.
A number of participants refused to participate after randomisation (three in the ‘Nutrimune®’
group, 21 in the fermented rice group and 17 in the placebo group). Upon a request for clariﬁcation
from EFSA, the applicant explained that the reasons for refusal were change in residence (n = 5),
withdrawal of informed consent (n = 12) and the use of ‘pre/pro/synbiotics or antibiotics’ after
randomisation but before treatment (n = 24). The Panel notes that the latter reason for withdrawal
was unequally distributed among the study groups (one in the ‘Nutrimune®’, 12 in the fermented rice,
and 11 in the placebo group).
The primary outcome of the study was the proportion of children experiencing at least one episode
of CID affecting the respiratory or the GI tracts. The secondary outcomes included the proportion of
children with recurrent CID (i.e. ≥ 3 episodes), the total number of CID’s, the use of medications
(antipyretics, antibiotics or steroids), number of visits to the emergency department, number of
paediatric visits and number of hospitalisations. Markers of innate (a- and b defensins, and cathelicidin
LL-37) and acquired (secretory immunoglobulin A) immunity were measured in faeces at baseline and
at the end of the intervention.
A diary was ﬁlled in by the parents recording fever, GI and respiratory symptoms, use of
medications, visits to the emergency department, hospitalisations, and possible adverse events. There
were three planned visits with the family paediatricians (at 30, 60 and 90 days). Additional visits took
place whenever it was necessary because of the suspicion of an infectious disease or other morbidities.
The diagnosis of infectious diseases was made by paediatricians based on the evaluation of speciﬁc
symptoms according to standardised deﬁnitions.
Acute gastroenteritis was suspected by the presence of ≥ 3 episodes of soft/liquid faeces in 24 h
with or without fever or vomiting. The presence of URTI was deﬁned as the occurrence of ≥ 1
respiratory symptom(s) (runny nose, cough, sore throat, aphony, shortness of breath, otalgia,
otorrhoea, extroversion of tympanic membrane with or without hyperaemia) in the absence or
presence of ≥ 1 systemic symptoms(s) (fever, headache, restless, myalgia, irritability). The applicant
stated that the same deﬁnition of URTI was used in several previous studies (Hojsak et al., 2010;
Agustina et al., 2012; Maldonado et al., 2012). Upon a request from EFSA for clariﬁcation on whether
one of the symptoms listed above was sufﬁcient for the diagnosis of an URTI, the applicant explained
that all medical examinations were performed by the same family paediatrician for each child
throughout the whole study period and that the diary compiled by the parents served only to ﬂag
potential symptoms of infections and to trigger a visit with the family paediatrician. At these visits, the
paediatrician inspected the diary completed by the parents, performed a full physical examination and
then, using standard deﬁnitions based on clinical practice guidelines issued by national and
‘Nutrimune®’ and immune defence against pathogens
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international scientiﬁc societies,3 decided on the diagnosis. In a further request for clariﬁcation by
EFSA, the applicant speciﬁed that the acute occurrence of at least one symptom suggestive of rhinitis,
tracheitis, laryngitis, pharyngitis or acute otitis media, as reported in the diary, was mandatory for the
ﬁnal diagnosis of URTI, although a cluster of signs and symptoms were evaluated by the paediatrician
in line with the guidelines in all cases to make the ﬁnal diagnosis. Microbiological investigations were
not performed and the objective signs of cold (e.g. nasal mucus weight, nasal mucociliary clearance
function) were not used for diagnosis.
In response to a request for clariﬁcation by EFSA on the criteria used to exclude the most common
non-infectious causes of the signs and symptoms used for the diagnosis of URTI and GI infections
(i.e. differential diagnosis), the applicant conﬁrmed that children with antibiotic-associated diarrhoea
and children with diagnosis of allergic diseases were excluded from the study. In addition, the applicant
stated that possible newly developed allergies could have been detected by family paediatricians.
The Panel notes that the process and the criteria used for the diagnosis of infections reported in
the publication (Nocerino et al., 2015) and in the study report provided with the initial submission of
the application signiﬁcantly differ from those described in subsequent clariﬁcations obtained from the
applicant during scientiﬁc evaluation of the claim. In this context, the Panel assumes that the diagnosis
of URTI was made by physicians based on a medical history and a physical examination according with
accepted diagnostic standards, which are based on clusters of symptoms, as speciﬁed by the applicant
in its last clariﬁcation,3 and that at least one acute symptom suggestive of rhinitis, tracheitis, laryngitis,
pharyngitis or acute otitis media was needed (but not sufﬁcient) for the diagnosis. The Panel also
notes the exclusion of children with diagnosis of allergic diseases and/or under antibiotic treatment to
exclude the most common non-infectious causes of the signs and symptoms used for the diagnosis of
URTI and GI infections.
The vaccination status was identical among all studies groups. No child had received anti-rotavirus
or anti-inﬂuenza vaccine.
Fourteen participants dropped out during the study (lost to follow-up): four in the ‘Nutrimune®’,
ﬁve in the fermented rice and ﬁve in the placebo group. The ‘Intention to Treat (ITT)’ analysis was
performed in children who received at least one dose of the allocated intervention, and did not include
children who refused to participate after randomisation. The Panel notes that the ‘ITT’ analysis was a
full analysis set (FAS).
The main outcome of the study (i.e. the proportion of children experiencing at least one episode of
CID affecting the respiratory or the GI tracts) was assessed using FAS analysis, assuming that all
children with missing data (n = 14) had one CID. Binomial regression was used to calculate the
absolute risk difference for the occurrence of at least one CID in both intervention groups against the
placebo group.
Per protocol (PP) analyses were performed separately for acute URTI and acute GI infections. The
incidence rate ratio of CID in both intervention groups against the placebo group was estimated using
the Poisson regression analysis. Statistical analyses of secondary outcomes were performed in the PP
population only.
Changes in a-defensin, b-defensin, LL-37 and sIgA were analysed using a random effect linear
regression. The treatment 9 time interaction was calculated to assess changes in the immunological
markers for the intervention groups vs placebo at 3 months vs baseline. Immunological markers were
3 Rhinitis was deﬁned by the acute onset of rhinorrhoea (mucus secretion from the nose), nasal airways obstruction with or
without cough, sneezing, fever and conjunctivitis (Kliegman et al., 2009; De Martino, 2012; Principi et al., 2012).
Tracheitis was deﬁned by acute onset of signs and/or symptoms of airway obstruction or impending respiratory failure or both.
These symptoms may include tachypnoea, cough, mucus production or fever (Kliegman et al., 2009; Principi et al., 2012).
Laryngitis was deﬁned by the acute onset of inspiratory wheezing with cough and hoarse voice with or without chest indrawing
and stridor (Kliegman et al., 2009; De Martino, 2012; Principi et al., 2012).
Pharyngitis (or sore throat) was deﬁned by the acute onset of inﬂammation of the pharyngeal tonsils that may be accompanied
by other nonspeciﬁc symptoms, including cough, pharyngodynia and fever (Kliegman et al., 2009; De Martino, 2012).
Acute otitis media was deﬁned by the acute onset of symptoms (otalgia, otorrhoea, irritability, fever) and the result of a careful
otoscopic examination to conﬁrm the presence of inﬂammatory changes in the lymphatic membrane. These signs include
bulging with or without erythema and one or more of the acute symptoms. For the otoscopic examination, this entailed the
demonstration of tympanic membrane inﬂammation based on: (a) otoscopic ﬁndings of marked erythema of the tympanic
membrane, with bulging and the absence mobility due to the presence of middle ear effusion or (b) otoscopic ﬁndings of a
yellowish membrane by observing in transparency the presence of purulent material in the middle ear or (c) the presence of
spontaneous perforation with otorrhoea. Redness alone of the tympanic membrane was considered insufﬁcient for the
diagnosis (Kliegman et al., 2009; Marchisio et al., 2010; De Martino, 2012). In order to help the family paediatricians in
distinguishing acute otitis media from otitis media with effusion, a video provided by the American Association of Paeditricians
was used during the instructions provided at the two investigator meetings.
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loge-transformed (skewed distribution) to ensure homoscedasticity of residuals. Statistical analysis was
performed using SPSS 19.0 for Windows and Stata 14.1.
The statistical analysis was performed separately for each intervention group against the placebo
group.
The Panel considers that the results obtained in the fermented rice group are not relevant for the
scientiﬁc substantiation of a claim on ‘Nutrimune®’, the food that is the subject of this application, and
therefore are omitted in this opinion.
In the FAS analysis, the number of children with at least one CID was signiﬁcantly lower in the
‘Nutrimune®’ group (n = 73) than in the placebo group (n = 102; p < 0.0001). The absolute risk
difference in the occurrence of at least one CID was 29% (95% CI: 39% to 18%, p < 0.001) for
the ‘Nutrimune®’ group vs. placebo. The total number of CIDs was 129 in the ‘Nutrimune®’ group and
324 in the placebo group. No adverse events were noted in any of the groups.
In the PP analysis (children complying with the protocol), the proportion of children presenting at
least one episode of acute gastroenteritis was signiﬁcantly lower in the ‘Nutrimune®’ than in the
placebo group. The absolute risk difference in the occurrence of at least one episode of acute
gastroenteritis was 18% (95% CI: 28% to 8%, p < 0.001) for the ‘Nutrimune®’ group vs placebo.
The absolute risk difference in the occurrence of at least one episode of URTI was 22% (95% CI:
34% to 11%, p = 0.001) in the ‘Nutrimune®’ group vs placebo. The Incidence Rate Ratio (IRR)
calculated using Poisson regression was 0.36 (95% CI: 0.29–0.44, p < 0.001) in the ‘Nutrimune®’ group
vs placebo.
The proportion of subjects who experienced at least one episode of acute gastroenteritis (n = 18%
in ‘Nutrimune®’ vs 38% in placebo, p < 0.0001), rhinitis (n = 19% in ‘Nutrimune®’ vs 35% in placebo,
p = 0.003), otitis (n = 3% in ‘Nutrimune®’ vs. 18% in placebo, p < 0.0001), pharyngitis (n = 21% in
‘Nutrimune®’ vs 53% in placebo, p < 0.0001), laryngitis (n = 9% in ‘Nutrimune®’ vs 22% in placebo,
p = 0.005) and tracheitis (n = 36% in ‘Nutrimune®’ vs 49% in group, p < 0.018) was signiﬁcantly
lower in the ‘Nutrimune®’ group compared to placebo. Differences remained statistically signiﬁcant
(except for tracheitis) after Bonferroni correction. It was reported that the total number of episodes of
the individual URTIs was also signiﬁcantly lower in the ‘Nutrimune®’ group compared to placebo.
The odds ratio (OR) of receiving at least one medication were signiﬁcantly lower in the
‘Nutrimune®’ group compared to placebo (OR 0.26, 95% CI: 0.15–0.43). The number of children
taking at least one medication during the intervention was 41 in the ‘Nutrimune®’ group and 76 in the
placebo group. The additional number of paediatric visits was 142 in the ‘Nutrimune®’ group and 353
in the placebo group. Emergency visits or hospitalisations were not required.
The number of children with ≥ 3 CID episodes was lower in the ‘Nutrimune®’ group (n = 14) than
in the placebo group (n = 57, p < 0.001). The proportion of children with recurrent CID (i.e. ≥ 3) vs
those with one or two infectious episodes was 10% in the ‘Nutrimune®’ group and 37% in the placebo
group (p < 0.001 in Wald test, binomial regression).
Faecal a-defensin, b-defensin, LL-37 and sIgA signiﬁcantly increased in the ‘Nutrimune®’ group as
compared to placebo (p < 0.001 for all comparisons at 3 months vs baseline). An inverse association
was also reported between changes in a-defensin (q = 0.362, p = 0.004), b-defensin (q = 0.256,
p = 0.047), LL-37 (q = 0.296, p = 0.012) and sIgA (q = 0.356, p = 0.001) and the total number of
CIDs at the end of the intervention.
The Panel considers that this study shows an effect of ‘Nutrimune®’ on immune defence against
pathogens in the GI tract and the URT. The Panel notes, however, inconsistencies in the reporting of
the process and criteria used for the diagnosis of URTI in the study.
The second human intervention study submitted (Corsello et al., 2015, unpublished, claimed as
proprietary by the applicant) was a randomised, parallel, double-blind, placebo-controlled, two-arm
study. The study was conducted in three Italian paediatric centres (i.e. Naples, Palermo and Milan) and
investigated the effect of ‘Nutrimune®’ on the incidence of CID in a group of healthy children
attending day care or preschool at least 5 days a week.
Except for the absence of a third study arm receiving fermented rice, the study protocol (inclusion
and exclusion criteria for the selection of subjects, study products and doses used, duration of the
intervention, assessment of compliance, vaccination status, primary and secondary outcomes, and
statistical analysis) was as described for the previous intervention study (Nocerino et al., 2015). In
addition, the number of days lost from school and the number of working days lost by parents were
assessed. The study was conducted between December 2014 and March 2015.
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It was calculated that 73 children per group were needed for a power of 0.90 at a = 0.05 assuming
the occurrence of at least one episode of infection in 79% of the children in the placebo group and in
50% of the children in intervention group.
A total of 146 children were randomised (using a computer-generated randomisation sequence) to
receive either ‘Nutrimune®’ (n = 73, 53% male, mean age 39 months) or placebo (n = 73, 62% male,
mean age 45 months) for 3 months. All randomised children received the allocated intervention.
Twenty children dropped out during the study (lost to follow-up): seven in the ‘Nutrimune®’ and 13
in the placebo group. The ITT analysis on the primary outcome was conducted in the 146 children
randomised, assuming that all children lost to follow-up had one episode of CID. The PP analysis was
performed in the 126 children who completed the study and complied with the protocol as planned
(66 in the ‘Nutrimune®’ and 60 in the placebo group).
The results of ‘pooled’ ITT and PP analyses for the primary and secondary outcome variables were
provided. However, the Panel noted that the multicentre design had not been considered in data analysis.
Following a request for clariﬁcation by EFSA, the applicant acknowledged that the study was
designed to detect a given effect size on the primary outcome on the ‘pooled’ sample of children
recruited, and thus the potential role of study centre had to be taken into account in secondary
analyses. In this context, the applicant provided the results of a binomial regression model using
treatment and centre (0 = Naples; 1 = Milan and 2 = Palermo) as discrete variables.
The Panel notes that the vast majority of the participants were recruited in one centre (i.e. 105 in
Naples, 17 in Milan and 24 in Palermo), that the statistical analysis provided is not appropriate for the
study data (i.e. the same weight is given to all centres, regardless of their sample size), and that if the
study was not planned, designed, randomised and analysed as a multicentre study (as acknowledged
by the applicant), the aleatory recruitment of subjects in three different centres is not duly justiﬁed.
The Panel also notes that this study shares the inconsistencies in the reporting of the process and
criteria used for the diagnosis of URTI identiﬁed for the study by Nocerino et al. (2015).
The Panel considers that this study is at high risk of bias and no conclusions can be drawn for the
scientiﬁc substantiation of the claim.
The Panel notes that one human intervention study from which conclusions could be drawn showed
an effect of ‘Nutrimune®’ on immune defence against pathogens in the GI tract and the URT. The
Panel also notes, however, inconsistencies in the reporting of the process and criteria used for the
diagnosis of URTI, and that the results of the study have not been replicated.
3.3.2. Animal efﬁcacy studies
The applicant also provided one animal study for the scientiﬁc substantiation of the claim (Zagato
et al., 2014). Twenty mice were fed with ‘Nutrimune®’ or non-fermented milk (control) for 10 days and
then were challenged intragastrically with a lethal dose of Salmonella Typhimurium FB62 (106 cfu in
200 lL carbonate buffer). Mice receiving ‘Nutrimune®’ survived slightly, but statistically signiﬁcantly,
longer than mice in the control group.
The Panel considers that the results from this animal study may be in line with an effect of
‘Nutrimune®’ on defence against pathogens in the GI tract, albeit the effects shown are small, and
found in a model that is very different from a normal infection in humans.
3.3.3. Mechanism of action
The applicant claims that the observed negative correlation between increased faecal
concentrations of a- and b-defensins, cathelicidin (LL-37) and secretory IgA (sIgA) and the number of
infectious episodes in human intervention study (Nocerino et al., 2015), indicates that the biological
mechanism behind this effect may be at least in part via a positive stimulation of innate and acquired
immunity. ‘Nutrimune®’ signiﬁcantly increased faecal concentrations of a- and b-defensins, LL-37 and
sIgA in the human intervention study provided (Nocerino et al., 2015), and it was speculated that the
ingredient reaches the gut in active form to enable direct effects on intestinal cells (both epithelial and
immune cells) and may explain the reduced risk for GI infections.
As for the URTI, the applicant argues that ‘the immune modulatory effect of ‘Nutrimune®’ may be
transmitted to immune components (e.g. T and B lymphocytes) able to reach other mucosa-associated
lymphoid tissues, e.g. in the respiratory tract’, and that ‘IgA-producing B cells generated at intestinal
sites may migrate to other mucosal sites to offer protection against invading pathogens’. However, no
evidence was provided by the applicant to support this statement.
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The applicant also states that two references submitted as abstracts (Sarno et al., 2014; Paparo
et al., 2015) could provide evidence for a non-immune defence mechanism by which ‘Nutrimune®’
could provide defence against pathogens in the GI tract (i.e. ‘by stimulation of epithelial cells growth,
differentiation, permeability and mucus production through a direct interaction with the enterocytes’).
The Panel notes that the information provided in these two abstracts is not sufﬁcient to allow a full
scientiﬁc evaluation.
Finally, the applicant claims that ‘Nutrimune®’ showed ‘strong anti-inﬂammatory’ effects in vitro by
reducing IL-12p70 production while preserving the production of IL-10 by human monocyte-derived
dendritic cells stimulated with Salmonella Typhimurium; ex vivo, by reducing the capacity of Salmonella
Typhimurium to cause inﬂammation and tissue destruction in colon explants; and in vivo, by its
protective effects against dextran sulfate sodium (DSS)-induced colitis in mice (Zagato et al., 2014).
The Panel notes that although an anti-inﬂammatory response is part of the physiological response to a
pro-inﬂammatory stimulus (such as an infectious agent), no evidence has been provided that this is
part of the mechanism by which ‘Nutrimune®’ exerted an effect in humans. The Panel also notes that
the animal model used in the second study provided (i.e. the DSS-colitis murine model) is not
appropriate to substantiate a claim on infections.
The Panel considers that the results of the studies discussed in this section do not provide evidence
for a plausible mechanism by which ‘Nutrimune®’ could exert the claimed effect in vivo in humans.
3.3.4. Weighing of the evidence
In weighing the evidence, the Panel took into account that one human intervention study from which
conclusions could be drawn showed an effect of ‘Nutrimune®’ on immune defence against pathogens in the
GI tract and the URT, and that the results from one animal study could support an effect of ‘Nutrimune®’ on
defence against pathogens in the GI tract. The Panel also took into account the inconsistencies in the
reporting of the process and criteria used for the diagnosis of URTI in the human intervention study, that
the results of this study have not been replicated, and that no evidence was provided for a plausible
mechanism by which ‘Nutrimune®’ could exert the claimed effect in vivo in humans.
The Panel concludes that the evidence provided is insufﬁcient to establish a cause and effect
relationship between the consumption of ‘Nutrimune®’ and immune defence against pathogens in the
GI and upper respiratory tracts.
4. Conclusions
On the basis of the data presented, the Panel concludes that:
• The food constituent ‘Nutrimune®’ (a pasteurised cow’s skim milk fermented with
Lactobacillus paracasei CBA L74), which is the subject of the health claim, is sufﬁciently
characterised.
• The claimed effect proposed by the applicant is ‘support of the immune defence in the
gastrointestinal and upper respiratory tract’. The target population proposed by the applicant is
young children aged 12–48 months. Immune defence against pathogens in the GI and upper
respiratory tracts is a beneﬁcial physiological effect.
• The evidence provided is insufﬁcient to establish a cause and effect relationship between the
consumption of ‘Nutrimune®’ and immune defence against pathogens in the GI and upper
respiratory tracts.
Documentation provided to EFSA
1) Health claim application on ‘Nutrimune®’ and ‘immune defence against pathogens’ pursuant
to Article 14 of Regulation (EC) No 1924/2006 (Claim serial No: 0445_NL). Submitted by H.J.
Heinz Supply Chain Europe B.V., Nieuwe Dukenburgseweg 19, Nieuwe Dukenburgseweg 19,
The Netherlands.
2) This application was received by EFSA on 05/1/2016.
3) The scope of the application was proposed to fall under a health claim referring to disease
risk reduction.
4) On 28/1/2016, during the validation process of the application, EFSA sent a request to the
applicant to provide missing information.
5) On 20/2/2016, EFSA received the missing information as submitted by the applicant.
6) The scientiﬁc evaluation procedure started on 4/3/2016.
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7) On 17/3/2016, the Working Group on Claims of the NDA Panel agreed on a list of
questions for the applicant to provide additional information to accompany the application.
The scientiﬁc evaluation was stopped on 28/ 4/2016 in compliance with Article 18(3) of
Regulation (EC) No 1924/2006.
8) On 13/5/2016, EFSA received the requested information and the scientiﬁc evaluation was
restarted.
9) On 9/6/2016, the Working Group on Claims of the NDA Panel agreed on a list of questions
for the applicant to provide additional information to accompany the application. The
scientiﬁc evaluation was stopped on 8/7/2016 in compliance with Article 18(3) of Regulation
(EC) No 1924/2006.
10) On 26/7/2016, EFSA received the requested information and the scientiﬁc evaluation was
restarted.
11) On 6/9/2016, the Working Group on Claims of the NDA Panel agreed on a list of questions
for the applicant to provide additional information to accompany the application. The
scientiﬁc evaluation was stopped on 3/10/2016 in compliance with Article 18(3) of
Regulation (EC) No 1924/2006.
12) On 10/11/2016, EFSA received the requested information and the scientiﬁc evaluation was
restarted.
13) During its meeting on 14/12/2016, the NDA Panel, having evaluated the data, adopted an
opinion on the scientiﬁc substantiation of a health claim related to ‘Nutrimune®’ and
immune defence against pathogens.
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Abbreviations
cfu colony-forming units
CID Common Infectious Disease
DSS dextran sulfate sodium
FAS Full Analysis Set
GI gastrointestinal
IRR Incidence Rate Ratio
ITT Intention to Treat
NDA EFSA Panel on Dietetic Products, Nutrition and Allergies
PCR polymerase Chain Reaction
PP per protocol
RNA ribonucleic acid
URT upper respiratory tract
URTI upper respiratory tract infection
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